Serum antibodies to 25 myelin oligodendrocyte glycoprotein epitopes in multiple sclerosis and neuromyelitis optica： clinical value for diagnosis and disease activity  

作　　者：XU Yan ZHANG Yao LIU Cai-yan PENG Bin WANG Jian-ming ZHANG Xiao-jun LI Hai-feng CUI Li-ying 

机构地区：[1]Department of Neurology, Peking Union Medical CollegeHospital, China Beijing 100730 [2]Department of Neurology, Beijing Tongren Hospital, China Beijing100730 [3]Department of Neurology, Affiliated Hospital of Medical CollegeQingdao University, Qingdao, China Shandong 266071 [4]Correspondence to: Prof. CUI Li-ying, Department of Neurology,Peking Union Medical College Hospital, China Beijing 100730

出　　处：《Chinese Medical Journal》2012年第18期3207-3210,共4页中华医学杂志（英文版）

基　　金：This study was supported by grants from Beijing Natural Science Foundation （No. 7093128） and Peking Union Medical College Hospital （No. 2009115）.

摘　　要：Background Whether antibody to myelin oligodendrocyte glycoprotein （MOG） can be a diagnostic marker for multiple sclerosis （MS） is still controversial. Recent studies suggested that serum specific anti-MOG epitope antibody might be an MS specific marker. However, these studies did not include neuromyelitis optica （NMO） which might be proven to also have anti-MOG antibody. Hence, the present study was undertaken to investigate the clinical value of serum antibodies to 25 MOG epitopes in conventional MS （CMS） and NMO. Methods Serum anti-MOG epitope IgG was detected in 61 CMS patients, 54 NMO patients, and 77 healthy controls, using enzyme-linked immunosorbent assay （ELISA）. Results Anti-MOG27-38 IgG levels in both CMS and NMO patients were significantly higher than that in healthy controls （optical density （OD）： 0.64±0.38, 0.48±0.23 vs. 0.19±0.09; P=0.000）. CMS and NMO patients in relapse stage had significantly higher anti-MOG27-38 IgG level than patients in remission stage （OD： 0.55±0.14 vs. 0.24±0.09, P=0.027）. Conclusion Although serum anti-MOG epitope IgG could not differentiate MS from NMO, it may be a useful marker for monitoring disease activity.Background Whether antibody to myelin oligodendrocyte glycoprotein （MOG） can be a diagnostic marker for multiple sclerosis （MS） is still controversial. Recent studies suggested that serum specific anti-MOG epitope antibody might be an MS specific marker. However, these studies did not include neuromyelitis optica （NMO） which might be proven to also have anti-MOG antibody. Hence, the present study was undertaken to investigate the clinical value of serum antibodies to 25 MOG epitopes in conventional MS （CMS） and NMO. Methods Serum anti-MOG epitope IgG was detected in 61 CMS patients, 54 NMO patients, and 77 healthy controls, using enzyme-linked immunosorbent assay （ELISA）. Results Anti-MOG27-38 IgG levels in both CMS and NMO patients were significantly higher than that in healthy controls （optical density （OD）： 0.64±0.38, 0.48±0.23 vs. 0.19±0.09; P=0.000）. CMS and NMO patients in relapse stage had significantly higher anti-MOG27-38 IgG level than patients in remission stage （OD： 0.55±0.14 vs. 0.24±0.09, P=0.027）. Conclusion Although serum anti-MOG epitope IgG could not differentiate MS from NMO, it may be a useful marker for monitoring disease activity.

关 键 词：multiple sclerosis neuromyelitis optica myelin oligodendrocyte glycoprotein 

分 类 号：R744.51[医药卫生—神经病学与精神病学]